The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
- PMID: 32673741
- DOI: 10.1016/j.jhep.2020.06.013
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
Abstract
Background & aims: Acute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF.
Methods: A total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded.
Results: Three groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC).
Conclusions: Acute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. CLINICALTRIALS.
Gov number: NCT03056612.
Lay summary: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.
Keywords: Acute complications; Chronic liver disease; Non-elective admission; Outcome; Risk factors.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest None of the authors have conflicts of interest for the reported study. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Predicting development of ACLF.Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):531. doi: 10.1038/s41575-020-0355-z. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32759982 No abstract available.
-
Acute-on-chronic liver failure: The challenge of PREDICTing who and when.J Hepatol. 2020 Oct;73(4):755-756. doi: 10.1016/j.jhep.2020.07.029. Epub 2020 Aug 13. J Hepatol. 2020. PMID: 32800351 No abstract available.
-
Pre-acute-on-chronic liver failure in hepatitis B-related patients.J Hepatol. 2021 Feb;74(2):479-480. doi: 10.1016/j.jhep.2020.09.001. Epub 2020 Dec 2. J Hepatol. 2021. PMID: 33279256 No abstract available.
-
Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.J Hepatol. 2021 Feb;74(2):480-481. doi: 10.1016/j.jhep.2020.11.012. Epub 2020 Dec 2. J Hepatol. 2021. PMID: 33279257 No abstract available.
-
PREDICTing acute-on-chronic liver failure in patients with acute decompensation.J Hepatol. 2021 Feb;74(2):478-479. doi: 10.1016/j.jhep.2020.08.031. Epub 2020 Dec 3. J Hepatol. 2021. PMID: 33279258 No abstract available.
Similar articles
-
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study.Liver Int. 2024 Jan;44(1):72-82. doi: 10.1111/liv.15734. Epub 2023 Sep 18. Liver Int. 2024. PMID: 37718730
-
Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis.JHEP Rep. 2022 Jul 5;4(10):100529. doi: 10.1016/j.jhepr.2022.100529. eCollection 2022 Oct. JHEP Rep. 2022. PMID: 36052222 Free PMC article.
-
Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.United European Gastroenterol J. 2021 May;9(4):427-437. doi: 10.1002/ueg2.12089. United European Gastroenterol J. 2021. PMID: 34050619 Free PMC article.
-
Acute-on-chronic liver failure in cirrhosis.Nat Rev Dis Primers. 2016 Jun 9;2:16041. doi: 10.1038/nrdp.2016.41. Nat Rev Dis Primers. 2016. PMID: 27277335 Review.
-
Prognostic assessment of liver cirrhosis and its complications: current concepts and future perspectives.Front Med (Lausanne). 2023 Sep 14;10:1268102. doi: 10.3389/fmed.2023.1268102. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37780566 Free PMC article. Review.
Cited by
-
The Clinical Courses and Prognosis of Cirrhotic Patients after First Acute Decompensation: Prospective Cohort Study.Diagnostics (Basel). 2023 Dec 20;14(1):14. doi: 10.3390/diagnostics14010014. Diagnostics (Basel). 2023. PMID: 38201324 Free PMC article.
-
Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.Front Immunol. 2021 Apr 2;12:661182. doi: 10.3389/fimmu.2021.661182. eCollection 2021. Front Immunol. 2021. PMID: 33868313 Free PMC article. Review.
-
A new model for identification of HBV-related pre-ACLF.JHEP Rep. 2022 Aug 17;4(10):100554. doi: 10.1016/j.jhepr.2022.100554. eCollection 2022 Oct. JHEP Rep. 2022. PMID: 36119720 Free PMC article. No abstract available.
-
microRNA associated with hepatocyte injury and systemic inflammation may predict adverse outcomes in cirrhotic patients.Sci Rep. 2024 Oct 11;14(1):23831. doi: 10.1038/s41598-024-72416-w. Sci Rep. 2024. PMID: 39394217 Free PMC article.
-
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.BMJ Open. 2024 Feb 14;14(2):e079309. doi: 10.1136/bmjopen-2023-079309. BMJ Open. 2024. PMID: 38355195 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical